The report covers emerging Type 1 Diabetes drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Type 1 Diabetes treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Type 1 Diabetes: An Overview
Diabetes is a chronic metabolic condition characterized by high or low blood glucose (or blood sugar) levels, leading to significant damage to the heart, blood vessels, eyes, kidneys, and nerves over time. The rationale behind developing diabetes incorporates two factors: insufficient insulin production (produced by the pancreas and reduced blood glucose) or unsatisfactory cell response to insulin action.
Clinically, diabetes is classified into three types, type 1 diabetes (TD-1), Type 1 Diabetes (TD2), and gestation diabetes. TD-1 is the consequence of an autoimmune reaction that causes the pancreas to suppress insulin-producing β-cells and leads to severe insulin deficiency. TD2 is linked with a genetic factor, which is far more common and substantially correlates with obesity and unhealthy lifestyles. Insulin resistance (inadequate reaction of peripheral cells to insulin) and pancreatic β-cell dysfunction (impaired insulin secretion) are marked by Type 1 Diabetes, leading to relative insulin deficiency.
Type 1 diabetes is the most common type of diabetes among children, however, type 1 diabetes can occur at any age. Generally considered 5-10% of the diabetes patient pool. The typical symptoms of type 1 diabetes include excessive thirst, blurred vision, dry mouth, upset stomach and vomiting, bedwetting, frequent urination, unexplained weight loss, fatigue, labored breathing, lack of energy, and constant hunger. In patients having extreme type 1 diabetes, the symptoms include a fruity odor to the breath, belly pain, and rapid breathing.
As per DelveInsight, the Type 1 Diabetes therapeutics market is anticipated to evolve immensely in the coming years owing to the increasing prevalent population of Diabetes, increased healthcare spending worldwide, and the expected launch of emerging drugs in the market. Currently, key players such as Provention Bio, Oramed, Eli Lilly, Novo Nordisk, REMD Biotherapeutics, and several others are actively working in the Type 1 Diabetes therapeutics market.
Type 1 Diabetes Market Key Facts
-
According to the National Diabetes Statistics Report (2020), 34.2 million people in the United States have diabetes in 2018, accounting for 10.5% of the total population.
-
According to the Centers for Disease Control and Prevention (2020), 28.7 million people of all ages, or 8.7% of the US population, were diagnosed with diabetes in 2019. 283,000 children and adolescents younger than age 20 years or 35 per 10,000 US youths have been diagnosed of diabetes. This includes 244,000 with type 1 diabetes, accounting for 10.5% of the total population.
-
As per The Ministry of Health, Labor and Welfare (2020), reported that 14.5% of the Japanese population was strongly suspected of having diabetes (A1C 6.5% or higher or treated for diabetes).
-
As per the German Diabetes Society (2022), about 341,000 people in Germany have type 1 diabetes.
-
As per the National Diabetes Statistics Report (2020), 210,000 children and adolescents under the age of 20 in the United States were diagnosed with diabetes in 2018, of which 187,000 people had type 1 diabetes diagnosis. By the coming year, these cases are expected to increase).’
‘
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Type 1 Diabetes pipeline therapies. It also thoroughly assesses the Type 1 Diabetes market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Type 1 Diabetes drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Type 1 Diabetes Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Type 1 Diabetes epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Type 1 Diabetes epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Type 1 Diabetes Epidemiology, Segmented as –
-
Total Prevalent Cases of Type 1 Diabetes
-
Treated cases of Type 1 Diabetes
-
Total diagnosed prevalent cases of Type 1 diabetes
-
Total age-specific prevalent diagnosed cases of Type 1 Diabetes
-
Total gender-specific prevalent diagnosed cases of Type 1 Diabetes
Type 1 Diabetes Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Type 1 Diabetes market or expected to be launched during the study period. The analysis covers the Type 1 Diabetes market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Type 1 Diabetes drugs based on their sale and market share.
The report also covers the Type 1 Diabetes pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Type 1 Diabetes companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Type 1 Diabetes Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/type-1-diabetes-market
Type 1 Diabetes Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Type 1 Diabetes. Currently, Provention Bio is leading the therapeutics market with its Type 1 Diabetes drug candidates in the most advanced stage of clinical development.
Type 1 Diabetes Companies Actively Working in the Therapeutics Market Include
Adocia, Amytrx, Anelixis Therapeutics, Arecor, AstraZeneca, Avotres, Bioprojet, Diamyd Medical, Dompe Pharmaceutical, Eli Lilly, Gan&Lee Pharmaceuticals, Histogen, ImCyse, Kamada, Landos Biopharma, Novartis, Novo Nordisk, Oramed, Panbela Therapeutics, Precigen ActoBiotics, Prevention Bio, REMD Biotherapeutics, TikoMed, Tolerion, Vertex Pharmaceuticals, Zealand Pharma, and many others.
Emerging and Marketed Type 1 Diabetes Therapies Covered in the Report Include:
-
AG019: Precigen ActoBiotics
-
AMTX 100: Amytrx
-
Basal insulin-Fc: Eli Lilly
-
Emricasan: Histogen
-
IMCY-0098: ImCyse
-
Insulin icodec: Novo Nordisk
-
Iscalimab: Novartis
-
Ladarixin: Dompe Pharmaceutical
-
LY3209590: Eli Lilly and Company Therapeutics
-
MHS552: Novartis
-
NNC0471-0119: Novo Nordisk
-
ORMD-0801: Oramed
-
Teplizumab: Prevention Bio
-
Volagidemab: REMD Biotherapeutics
-
VX-880: Vertex Pharmaceuticals
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/type-1-diabetes-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Type 1 Diabetes Competitive Intelligence Analysis
4. Type 1 Diabetes Market Overview at a Glance
5. Type 1 Diabetes Disease Background and Overview
6. Type 1 Diabetes Patient Journey
7. Type 1 Diabetes Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Type 1 Diabetes Treatment Algorithm, Current Treatment, and Medical Practices
9. Type 1 Diabetes Unmet Needs
10. Key Endpoints of Type 1 Diabetes Treatment
11. Type 1 Diabetes Marketed Therapies
12. Type 1 Diabetes Emerging Drugs and Latest Therapeutic Advances
13. Type 1 Diabetes Seven Major Market Analysis
14. Attribute Analysis
15. Type 1 Diabetes Market Outlook (In US, EU5, and Japan)
16. Type 1 Diabetes Companies Active in the Market
17. Type 1 Diabetes Access and Reimbursement Overview
18. KOL Views on the Type 1 Diabetes Market
19. Type 1 Diabetes Market Drivers
20. Type 1 Diabetes Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/type-1-diabetes-market
Other Trending Healthcare Reports by DelveInsight
“Goitre Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Goitre market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Goitre market.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/